Parexel Acquires Vitrana to Integrate AI-Enabled Pharmacovigilance Platform

What You Should Know

Parexel has acquired Vitrana, a provider of an AI-enabled, end-to-end pharmacovigilance (PV) technology platform.The acquisition allows Parexel to provide a fully integrated model where a single partner is responsible for both PV technology and services.The acquired platform is system-agnostic, integrating with any existing safety database to improve accuracy and cycle times.Key operational benefits include improved EDC-to-safety integration, streamlined Serious Adverse Event (SAE) reconciliation, and digital adverse event reporting for patients.Vitrana will initially operate as “Vitrana – a Parexel Company” as it aligns with Parexel’s Patient Safety Services organization.

The clinical development landscape is facing a rapid increase in regulatory volume and data complexity. To address these challenges, Parexel, a global clinical development partner, has acquired Vitrana to incorporate intelligent automation into its patient safety operations. This move completes Parexel’s AI-enabled suite, which now spans the entire development lifecycle from regulatory submissions to trial execution and post-approval safety monitoring.

By integrating Vitrana’s technology, Parexel aims to shift from a fragmented service model to a unified ecosystem. This integrated approach is designed to provide life sciences customers with better pricing flexibility, streamlined vendor management, and a faster path to resolving safety issues through a singular clinical and technical roadmap.

AI-Powered Safety and Compliance

The core of the Vitrana acquisition is a technology platform that leverages AI to accelerate end-to-end PV processes. Because the platform is system-agnostic, it can be deployed alongside any safety database a customer currently utilizes. This flexibility allows sponsors to enhance their compliance and “first-time quality” without the need for a total infrastructure overhaul.

Sanjay Vyas, President of Patient Safety Services at Parexel, noted that the acquisition allows the firm to deliver “year-over-year operational and efficiency gains” while maintaining high quality standards. By automating routine data processing, Parexel intends to free up human safety experts to focus on complex product and patient safety analysis.

Reducing Burden Across the Clinical Ecosystem

The acquisition provides tangible improvements for various stakeholders in the clinical trial process:

For Investigative Sites: Improved integration between Electronic Data Capture (EDC) systems and safety databases reduces manual entry and speeds up SAE reconciliation.For Patients: New digital reporting channels provide an intuitive way to report adverse events, potentially improving the volume and accuracy of patient-reported safety data.For Sponsors: A single-partner model for both technology and services simplifies the management of the pharmacovigilance lifecycle.

Mohit Gupta, President and CEO of Vitrana, expressed that joining Parexel will allow the Vitrana team to scale their technology globally, providing enhanced efficiency and compliance to a broader range of international customers.